GlaxoSmithKline

Top of the morning to you. And a fine one, it is. Although a bit cloudy here in New England, our spirits remain sunny. As you know, our philosophy, courtesy of the Morning Mayor, is quite simple: Every brand new day should be unwrapped like a precious gift. So while you tug on the ribbon, we will search for a cup of stimulation. And of course, here is your menu of morning tidbits. Have a smashing day and do keep us in mind for interesting developments…

The FDA issued inspection notices to Theranos for using its blood-collection device without securing needed approval; The FDA approved a virus called Imlygic for treating advanced-stage melanoma, a development that could herald a new age of viral therapies; The debate over drug prices, and complaints from consumer advocates about safety concerns, have fueled Senate Democratic resistance to pharma-friendly provisions in the 21st Century Cures Act; Walgreen Boots Alliance agreed to buy Rite Aid for about $9.4 billion, in a move that would create a drug store giant as companies across the US health care industry look for ways to bulk up; and Breast Cancer Now, a UK health charity, is urging Roche to drop the price of its Kadlyca key breast cancer drug before the National Health Service stops funding it next week.